# NEOGENOMICS, INC. (NEO) · Edgar & Edgarette company card

> Neogenomics (NEO) grew revenue 10.1% in FY2025 to $727 million, operating margin -15.9% against a 14.9% median for testing laboratories, equity 61.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1077183 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NEO) · [JSON](https://www.pops4.com/boards/company/NEO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $727M |
| Revenue growth, 1 year | 10.1% |
| Revenue growth per year | 10.7% |
| Operating margin | -15.9% (prior year -13.9%) |
| Net margin | -14.9% |
| Operating cash flow | $5M |
| Capital spending | $27M |
| Free cash flow | −$22M |
| Cash | $160M |
| Long-term debt | $342M |
| Total assets | $1.4B |
| Total equity | $837M |
| Equity ÷ assets | 61.5% |
| Return on equity | -12.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 1.46 (grey zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.68 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -15.9% in FY2025; free cash flow was negative: capital spending outran operating cash (-$21.8M in FY2025)
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $727.3M (FY2025), total debt $341.9M. Experience: revenue up 10.1% on the year, up 10.7% a year over 4 years; operating margin -15.9%, down from -13.9%. Soundness: equity 61.5% of assets, return on equity -12.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $698.5M and $901.2M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $654.9M to $963.8M. A statistical range, not company guidance. Against peers (8 filers, $50M+ revenue, its industry group): operating margin -15.9% against a 14.9% median; growth 10.1% against 5.2%.

Range logged 2026-10-06, receipt 2c628cf34ad4d9f3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 6, latest 2026-10-05 ([filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000069/0001077183-26-000069-index.htm))

## Recent filings

- 10-Q · filed 2026-10-28 · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000079/0001077183-26-000079-index.htm)
- 8-K · filed 2026-10-28 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000078/0001077183-26-000078-index.htm)
- 8-K · filed 2026-10-05 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000069/0001077183-26-000069-index.htm)
- 8-K · filed 2026-08-11 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000162828026055697/0001628280-26-055697-index.htm)
- 10-Q · filed 2026-07-28 · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000059/0001077183-26-000059-index.htm)
- 8-K · filed 2026-07-28 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000058/0001077183-26-000058-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001077183.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1077183

## Cite

POPS4, Edgar & Edgarette: NEOGENOMICS, INC. (NEO) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/NEO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

